Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (531-540 of 602) with videos related to

Pageof 61
Sort By:
American Journal of Clinical Pathology|September 2, 2023
Superior detection rate of plasma cell FISH using FACS-FISHMarie-France Gagnon, Sally M Midthun, James A Fangel, et al.
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Eclinicalmedicine|December 13, 2021
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivoNathan W Cummins, Jason Baker, Rana Chakraborty, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology|June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myelomaToshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Pageof 61

Showing results (531-540 of 602) with videos related to

Sort By:
Pageof 61
American Journal of Clinical Pathology|September 2, 2023
Superior detection rate of plasma cell FISH using FACS-FISHMarie-France Gagnon, Sally M Midthun, James A Fangel, et al.
Transplantation and Cellular Therapy|August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction TherapyMohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Eclinicalmedicine|December 13, 2021
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivoNathan W Cummins, Jason Baker, Rana Chakraborty, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology|June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myelomaToshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
Pageof 61